Calpurbatug (TRL1068)
Anti-infective biologic drug candidate
A native human monoclonal antibody that disperses bacterial biofilm, restoring the effectiveness of standard antibiotics against chronic infections. In an interim Phase 1 analysis, 75% of chronic prosthetic joint infection patients given a single dose plus standard antibiotics had biofilm burden below 100 CFU/mL after 7 days, versus roughly 15% historically, with no drug-related adverse events at the 6 mg/kg and 15 mg/kg doses. A Phase 2 trial in prosthetic joint infection patients undergoing a DAIR procedure is fully enrolled, with top-line data expected in Q2 2027.
- Native human monoclonal antibody cloned from human white blood cells
- Disrupts bacterial biofilm so standard antibiotics can reach the pathogen
- FDA Orphan Drug, Fast Track, and Qualified Infectious Disease Product designations
- Phase 2 trial in chronic prosthetic joint infection fully enrolled, top-line results expected Q2 2027
- Single-dose administration alongside standard-of-care antibiotics
Built for
Patients with chronic prosthetic joint infection and other biofilm-associated infections, reached through orthopedic surgeons and infectious-disease physicians in hospitals; near-term counterparties are pharmaceutical partners and specialist infectious-disease investors such as the AMR Action Fund.
